Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Olmesartan

SKU: orb1226259

Description

An angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. Hypertension Discontinued(In Vitro):Olmesartan (0.7-5 mM; 24, 48 and 72 h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode.(In Vivo):Repeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species.

Images & Validation

Key Properties

CAS Number144689-24-7
MW446.5016
Purity>98% (HPLC)
FormulaC24H26N6O3
SMILESO=C(C1=C(C(C)(O)C)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)O
TargetAngiotensin Receptor
SolubilityDMSO: ≥ 55 mg/mL

Bioactivity

In Vivo
Repeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species.
In Vitro
Olmesartan (0.7-5 mM; 24, 48 and 72 h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode. Cell Viability Assay Cell line: Human cervical cancer cell line (HeLa). Concentration: 0.7-5 mM Incubation time: 24, 48 and 72 h. Result: IC50s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

RNH 6270 | CS 088

Similar Products

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Protocol Information

Available Sizes

Select a size below

25 mg
$ 80.00
50 mg
$ 120.00
100 mg
$ 170.00
500 mg
$ 420.00